Merck appeals rofecoxib verdict

Rofecoxib, Merck, and the FDA.

The new england journal of medicine 2875 correspondence Rofecoxib, Merck, and the FDA to the editor: Merck has been proactive and conscientious in evaluating the cardiovascular profile of rofecoxib (Vioxx); Dr. Topol's remarks to the contrary in his Perspective article (Oct. 21 issue) 1 are false. First, his description of the time line obfus-cates the facts. The Food and Drug Administration (F...

Failing the public health--rofecoxib, Merck, and the FDA.

On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA) to market rofecoxib (Vioxx). On September 30, 2004, after more than 80 million patients had taken this medicine and annual sales had topped $2.5 billion, the company withdrew the drug because of an excess risk of myocardial infarctions and strokes. This represents the largest prescription-drug withdrawal in hi...

Merck Animal Health

Lancaster R.T., Foxcroft, G.R., Boland, M.R, Edwards, S. and Gordon, I., 1985. Fertility of sows treated with exogenous estradiol and/or gonadotropins to control postweaning estrus. Anim. Reprod. Sci., 8:365-373 In the first of two experiments 28 multiparous sows were allocated to one of the following treatments two days after weaning at approximately 35 days postpartum: (1) untreated; (2) i.m....

ATS Merck CME Newsletter

Charles M. Balch, MD, Professor of Surgery, Oncology and Dermatology, Johns Hopkins Medicine, Baltimore, reviewed the current version of the melanoma staging as well as new data on staging and prognosis contained in the 2008 version of the American Joint Committee on Cancer (AJCC) Melanoma Staging Schema. The final version of the melanoma staging criteria are embargoed until May 2009 and implem...

Advertising Appeals